CEOcast, Inc.
James Young
212-732-4300
Investor Relations
jyoung@ceocast.com

ImmunoCellular Therapeutics' ICT-107 Recognized As One Of Windhover's Top 10 Most Licensable Oncology Products

LOS ANGELES--(BUSINESS WIRE)-- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular" or the "Company") (OTCBB - News), a biotechnology company focused on the development of novel immune-based cancer therapies, announced today that ICT-107 was recognized as one of Windhover's Top 10 licensable oncology products. Windhover is a leading provider of business information to senior executives in the pharmaceutical, biotechnology, and medical device industries. ICT-107 is the Company's lead cancer vaccine candidate for the treatment of glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer.

ImmunoCellular was chosen by Campbell Alliance Business Development group using a variety of criteria, including mechanism of action, initial marketable indication and potential for follow-on indications to identify products and trends in the oncology space where license activity will most likely begin within the year.

"We are excited with the promise ICT-107 has demonstrated in patients with GBM, and are pleased that industry experts have recognized the potential of the drug candidate to attract partners to accelerate its develop," said Manish Singh, Ph.D. President and CEO of ImmunoCellular Therapeutics.

In ImmunoCellular's Phase I trial of ICT-107, the three-year overall survival is 55%, compared to 16% based on historical standard of care (SOC). The data from that trial shows that 38% of newly diagnosed patients who received ICT-107 continue to show no tumor recurrence after three years, compared to the historic

disease-free survival rate of 6% with SOC. Out of these patients, 19% remain disease-free after more than four years.

The Phase I clinical study was conducted in 16 newly diagnosed glioblastoma patients, who received three injections of ICT-107 in addition to standard treatment with surgery, radiation and chemotherapy. The company has previously reported a two-year survival rate of 80.2% in study patients, which compares favorably to the historic median two-year survival rate of 26.5% with SOC alone. No serious adverse events have been reported and minor side effects have been limited to fatigue, skin rash and pruritis.

About Windhover:

Windhover Information Inc, an Elsevier company, has provided analysis of the healthcare industry to decision-makers at all levels since the founding of its flagship publication, IN VIVO: The Business & Medicine Report, in 1983. Windhover provides its information and analysis in many formats, including print, electronic databases, international conferences and webinars. For more on the company's products and services, please see www.windhover.com.

About ImmunoCellular Therapeutics, Ltd.

IMUC is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. The Company recently commenced a Phase II trial of its lead product candidate, ICT-107, a dendritic cell-based vaccine targeting multiple tumor associated antigens for glioblastoma. To learn more about IMUC, please visit www.imuc.com.

Forward-Looking Statements

This press release contains certain forward-looking statements that are subject to a number of risks and uncertainties, the risk that IMUC will not be able to secure a licensee for development and commercialization of ICT-107 on favorable terms or at all; the need for substantial additional capital to fund development of ICT-107 through to commercialization; the risk that the safety and efficacy results obtained in the Phase I trial for the dendritic cell-based vaccine will not be confirmed in subsequent trials; the risk that the correlation between immunological response and progression-free and overall survival in the Phase I trial for ICT-107 will not be reflected in statistically significant larger patient populations; the need to satisfy performance milestones to maintain the vaccine technology licenses with Cedars-Sinai; the risks associated with adhering to projected preclinical or clinical timelines and the uncertainties of outcomes of development work for product

candidates; and the risk of obtaining patent coverage for the dendritic cell-based vaccine or that any patents covering this vaccine will provide commercially significant protection for this product candidate. Additional risks and uncertainties are described in IMUC's most recently filed SEC documents, such as its most recent annual report on Form 10-K, all quarterly reports on Form 10-Q and any current reports on Form 8-K. IMUC undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.